Clinical Trial Update: A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial results for SYL1801 in patients with neovascular age-related macular degeneration have been completed, focusing on dose-finding in wet AMD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• SYL1801

Snippet

Sponsor: Sylentis, S.A. | Conditions: Wet Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED